Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06550076 · ClinicalTrials.gov registry record · Phase 3
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Takeda.
- Active
- Registry status
- Phase 3
- Development phase
- 1,950
- Enrollment target
- 20
- Study locations
NCT06550076: Active Phase 3 study of Plaque Psoriasis, sponsored by Takeda.
NCT06550076 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Takeda. The registered enrollment target is 1,950 participants, above the 373-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (423% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06550076, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,950 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.
Primary Outcome
A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. An SAE is any untoward medical occurrence that at any dose: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event in the opinion of the healthcare provider, may jeopardize the participant or may require intervention to pre
Conditions Studied
Interventions
- DRUG TAK-279
Study Locations (20)
California
- Zenith Research, Inc. - Beverly Hills
- First OC Dermatology Research Inc. - Fountain Valley
- Center for Dermatology Clinical Research - Fremont
- Long Beach Research Institute - Long Beach
- Metropolis Dermatology Downtown LA - Probity - PPDS - Los Angeles
- UCLA University of California Los Angeles - Los Angeles
- Northridge Clinical Trials - Northridge
- UC Davis Dermatology Clinic - Sacramento
- TCR Medical Corporation - San Diego
- University Clinical Trials - San Diego
- Dermatology Institute and Skin Care Center - Santa Monica
- UNISON Clinical Trials (Shahram Jacobs md inc.) - Sherman Oaks
Alabama
- Total Dermatology - Birmingham
- University of Alabama Hospital - Whitaker Clinic - - Birmingham
- Cahaba Dermatology Skin Health Center - Hoover
Arizona
- Medical Dermatology Specialists - Phoenix
- Saguaro Dermatology Associates, LLC - Probity - PPDS - Phoenix
- Noble Clinical Research - Tucson
Arkansas
- Johnson Dermatology Clinic - Fort Smith
- Burke Pharmaceutical Research - Hot Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,950 participants |
| Start Date | 2024-09-04 |
| Est. Completion | 2026-05-07 |
| Phase | Phase 3 |
What the registry record for NCT06550076 still lists
NCT06550076 is an interventional study that assigns participants to a tested intervention. Its 1,950 participants enrollment target places it among the larger protocols in the corpus, above the 373-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (423% higher).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which TAK-279 is the first listed.
NCT06550076 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06550076 about?
NCT06550076 is a clinical study titled "A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis". The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Part...
What is the current status of trial NCT06550076?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,950 participants. The study started on 2024-09-04. Estimated completion is 2026-05-07.
What conditions does trial NCT06550076 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06550076?
The interventions under investigation include: TAK-279 (DRUG).
Who is sponsoring clinical trial NCT06550076?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06550076 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06550076's enrollment target sits among peer trials
1,950 2nd of 45 the highest of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04251052 · 1,956 participants · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
- NCT07321886 · 1,980 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI